- €6.65bn
- €7.52bn
- $2.09bn
Morgan Stanley sees selective medtech opportunities on growth recovery
Europe Research Roundup: BAT, GEA Group, Qiagen
Advisory: Alerts on Qiagen N.V. withdrawn
Advisory: Alerts on Qiagen N.V. withdrawn
Brief: Qiagen Supports Infectious Disease Research And Surveillance Efforts For Bundibugyo Ebolavirus Outbreak
Brief: Pomerantz Law Firm - Investigates Claims On Behalf Of Investors Of Qiagen N.V.
Brief: Qiagen To Appoint Metin Colpan As Honorary Chairman Of The Supervisory Board
Brief: QIAGEN NV Reports Full Results For Q1 2026
DiaSorin falls as Qiagen cuts outlook on QuantiFERON weakness
Qiagen shares hit hardest day in over 5 years on outlook downgrade, weak Q1 results
Netherlands' Qiagen cuts 2026 sales and EPS outlook
Brief: Qiagen Receives U.S. Clearance For Gastrointestinal Panels On Fully Automated Qiastat-Dx Rise Syndromic Testing System
Brief: Qiagen Reports Q4 Sales USD 540 Mln
Brief: QIAGEN Appoints Mark Stevenson To Supervisory Board
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports (updated)
Qiagen said to consider strategic options amid fresh takeover interest, Bloomberg reports
Brief: Qiagen Is Said To Consider Strategic Options Amid Fresh Interest- Bloomberg News
Brief: Qiagen Sets 2026 Priorities To Drive Growth
Brief: Qiagen Announces Details For Completion Of Synthetic Share Repurchase Of Up To Approximately $500 Mln